Robert F. Kester

Allosteric Activators of Glucokinase: Potential Role in Diabetes Therapy

Joseph Grimsby, Ramakanth Sarabu, Wendy L. Corbett et al. · Science · 2003 · 531 citations

Glucose Affinity, Glycosylation, Medicine +15

Discovery of Piragliatin—First Glucokinase Activator Studied in Type 2 Diabetic Patients

Ramakanth Sarabu, Fred T. Bizzarro, Wendy L. Corbett et al. · Journal of Medicinal Chemistry · 2012 · 97 citations · Full text

Glycobiology, Metabolomic Profiling, Pathology +21

Glucokinase activators as new type 2 diabetes therapeutic agents

Ramakanth Sarabu, Steven J. Berthel, Robert F. Kester et al. · Expert Opinion on Therapeutic Patents · 2008 · 59 citations

Molecular Pharmacology, Gk Kinetics, Diabetes Management +13

Discovery, Structure−Activity Relationships, Pharmacokinetics, and Efficacy of Glucokinase Activator (2<i>R</i>)-3-Cyclopentyl-2-(4-methanesulfonylphenyl)-<i>N</i>-thiazol-2-yl-propionamide (RO0281675)

Nancy-Ellen Haynes, Wendy L. Corbett, Fred T. Bizzarro et al. · Journal of Medicinal Chemistry · 2010 · 45 citations

Pharmaceutical Science, Glycobiology, Glucose Homeostasis +22

Optimization of Benzodiazepinones as Selective Inhibitors of the X-Linked Inhibitor of Apoptosis Protein (XIAP) Second Baculovirus IAP Repeat (BIR2) Domain

Robert F. Kester, Andrew F. Donnell, Yan Lou et al. · Journal of Medicinal Chemistry · 2013 · 38 citations · Full text

X-linked Inhibitor, Xiap Bir3, Drug Target +14